Navigation Links
Save messengers -- modified mRNAs open up new therapeutic possibilities
Date:2/7/2011

Defects in the genome are the cause of many diseases. Gene therapy direct replacement of mutant genes by intact DNA copies offers a means of correcting such defects. Now a research team based at the Medical Center of the University of Munich, and led by Privatdozent Dr. Carsten Rudolph, has taken a new approach that avoids DNA delivery. The team shows for the first time that chemical modification of mRNAs (the metabolically active molecules derived from genomic DNA that programs protein synthesis) provides a promising alternative to DNA-based procedures. In contrast to the latter, the modified RNAs do not increase the risk of cancer, and do not induce frequently observed severe immune reactions seen with DNA or unmodified mRNA. The researchers show that the new method is life-saving in mice with a congenital lethal lung defect. "These results clearly demonstrate the therapeutic potential of our mRNAs," says Rudolph. (Nature Biotechnology, 7 February 2011)

Gene therapy offers great potential for the treatment of both congenital and acquired diseases that are otherwise not amenable to other treatments. However, the approaches that have been tested so far are associated with serious side-effects. The use of engineered viruses to introduce intact genes into the cellular genome are associated with an increased risk of developing leukaemia, and can provoke strong immune reactions. Nonviral vectors, on the other hand, tend to be inefficient delivery vehicles. The new RNA-based method displays neither of these disadvantages. "Chemical modification of the mRNA prevents it from activating the immune system, so that no inflammatory reaction ensues," says Rudolph. "Furthermore, in contrast to conventional mRNA, the modified mRNA can be administered repeatedly, is more stable and is effective at very low doses."

The new method, referred to as Transcript Therapy by its inventors, opens up new opportunities for targeted treatments. The modified mRNAs shuttle genetic information into cells in a form that can be used directly for the production of therapeutically active proteins. In addition to their potential for the treatment of genetic diseases, they represent an alternative to established protein-based treatment regimes. The researchers demonstrated the efficacy of the latter application in a mouse model. A single intramuscular injection of mRNAs coding for the hormone erythropoetin, which stimulates the differentiation of red blood cells, led to a significant increase in erythrocyte counts four weeks later.

The team also employed a mouse model to show that the technique can effectively be used to treat a genetic disease. For this, they chose a strain with a lethal congenital lung defect, caused by its inability to make surfactant protein B (SP-B). Regular application of mRNA for SP-B, as an aerosol, to the lungs of the mutant mice restored lung function, and the effect persisted for the duration of the study. Rudolph sees great scope for transcript therapy in regenerative medicine and the treatment of metabolic diseases, and hopes to test the efficacy of modified mRNAs in a clinical setting over the next few years.


'/>"/>

Contact: Dr. Carsten Rudolph
Carsten.Rudolph@med.uni-muenchen.de
49-895-160-7711
Ludwig-Maximilians-Universitt Mnchen
Source:Eurekalert

Related medicine news :

1. NIH Stem Cell Guidelines Should Be Modified, UCSF Team Reports
2. Adults demonstrate modified immune response after receiving massage, Cedars-Sinai researchers show
3. New On the Menu: Genetically Modified Salmon?
4. FDA Advisers Weigh Approval of Genetically Modified Salmon
5. FDA Advisers Consider Approval of Genetically Modified Salmon
6. Consumer Activists Want Modified Salmon to Be Labeled
7. New therapeutic target for most common solid cancer in childhood?
8. UC studies show marijuana has therapeutic value, reports to legislature
9. United Therapeutics Corporation Withdraws European Marketing Authorization Application for Tyvaso for the Treatment of Pulmonary Arterial Hypertension
10. Elements Therapeutic Massage Announces Franchise Expansion Plan for Massachusetts
11. Castrate-Metastatic Prostate Cancer: Therapeutic Considerations for Advanced Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... ... April 28, 2016 , ... Horizon Blue Cross Blue Shield ... hospitals to make transformative changes in how health care is delivered and financed ... in discussing breakthroughs in cellular medicine to treat disease. After accepting an invitation ...
(Date:4/28/2016)... ... April 28, 2016 , ... One way to ignore solid evidence ... unfortunately true. But we toss the baby out with the bathwater when we ignore ... for identifying higher-quality studies and otherwise making better use of education policy research. , ...
(Date:4/28/2016)... (PRWEB) , ... April 28, 2016 , ... ... leader in Aesthetic Surgery Education and Anzu®, developers of the AnzuMedical™ Knowledge ... Nationwide Plastic Surgery Collaborative Residency Network. The platform is scheduled to launch in ...
(Date:4/28/2016)... ... April 28, 2016 , ... A first-time look at workers’ compensation claims in ... Workers Compensation Research Institute (WCRI) announced, and that costs per claim were ... Kentucky, 16th Edition , found that indemnity costs per claim and benefit delivery expenses ...
(Date:4/28/2016)... ... April 28, 2016 , ... Metabolic Nutrition today announced ... week’s 2016 Europa Games Get Fit and Sports Expo in Orlando, Florida. ... Orlando Expo coming up April 29-30, was selected as the perfect event to introduce ...
Breaking Medicine News(10 mins):
(Date:4/28/2016)... April 28, 2016 Oramed Pharmaceuticals Inc. ... pharmaceutical company focused on the development of oral drug delivery ... upcoming PIONEERS 2016 conference, presented by Joseph Gunnar ... New York . Nadav Kidron , ... conference. Presentation Details:   PIONEERS ...
(Date:4/28/2016)... Calif. , April 28, 2016 /PRNewswire/ ... Validation Lifecycle Management Solutions (VLMS) today announced ... and services for sufferers of chronic kidney ... System to manage their corporate validation process. ... seeking a software solution to manage their ...
(Date:4/28/2016)... April 28, 2016 New ... 2016" is a report that provides an overview ... R&D pipelines by identifying new targets and MOAs ... Company Profiles discussed in this H1 2016 Osteoarthritis ... Srl, AbbVie Inc., Abiogen Pharma S.p.A., Ablynx NV, ...
Breaking Medicine Technology: